Tempus AI signs multi‑year oncology data and AI platform deal with Bristol Myers Squibb through 2031
Tempus AI announced a multi‑year agreement under which Bristol Myers Squibb will license de‑identified multimodal oncology data and gain dedicated access to Tempus’s Lens AI platform for drug discovery. The partnership runs through 2031 and expands an existing collaboration that also includes clinical‑trial design support. Tempus CEO Eric Lefkofsky said the deal gives BMS powerful AI tools to accelerate precision oncology research.
Why it matters
Tempus shares jumped 6% after the announcement, reflecting market belief that the data licensing business is a key growth driver. The deal adds a large, recurring revenue stream for Tempus’s most profitable segment, data licensing and modeling.
Key facts
- 1The agreement runs through 2031. gurufocus.com
- 2BMS will license Tempus’s multimodal oncology data. gurufocus.com
- 3BMS will receive access to Tempus’s Lens AI platform for oncology drug development. gurufocus.com
- 4The deal includes $137.5 million from BMS and $55 million from Pathos AI for patient records. marketscreener.com
- 5Tempus shares rose 6% on the news. finance.yahoo.com
- 6Data licensing and modeling revenue grew 36% in Q2 and gross margin reached 62.7% in 2025. finance.yahoo.com
Summary written by AlphAI AI Desk from 6 of 6 sources. Not investment advice. Figures are as stated by the linked sources.